We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.


Annals of Medicine

In the Oncology section of Annals of Medicine we consider for publication the latest advances in:

Cancer Medicine Cancer Therapeutics Carcinogenesis Clinical Oncology
Hematopoietic Malignancies Onco-Biology Preclinical Cancer Models Proof-of-Principle Clinical Trials
Solid Tumors Targeted Therapy Translational Research
Annals of Medicine

Q1 Rank

Two-Year Impact Factor 3.243
Five-Year Impact Factor 3.840

MEDLINE® Indexed

CiteScore 5.70

Meet the Section Editor

Rakesh Kumar, Rajiv Gandhi Centre for Biotechnology, India

Dr. Kumar is a Distinguished Professor and National Chair in Cancer Research at the Rajiv Gandhi Centre for Biotechnology-India, while holding visiting/adjunct professorships at the Virginia Commonwealth University School of Medicine and Rutgers NJ Medical Center. Dr. Kumar is a cancer biologist with over 34 years of experience in basic, translational and preclinical cancer research. He has served as a faculty member and administrator at the US Medical and Cancer Centers, including Memorial Sloan-Kettering Cancer Center and UT MD Anderson Cancer Center. For 25 years, Dr. Kumar has been actively contributed to the peer-review process for multiple national and international funding agencies. Dr. Kumar has shared his cancer research experience by delivering over 270 invited lectures at national and international scientific forums, training over 65 students, physician scientists and postdoctoral fellows, and editing or co-editing eight books or thematic volumes in cancer research and therapeutics.

Why is Annals of Medicine the Best Publication for Your Research?

Fully open access, general medical journal publishing articles under a CC BY license, allowing maximum sharing and reuse of articles to our international readership;

Publishing all scientifically valid research, including reporting of negative and null data, from translational to clinical research in all disciplines and therapy areas;

Led by an international editorial team of subject experts who ensure a constructive and rigorous peer review process;

Your research is promoted via a tailored, multi-channel approach to maximize visibility, readership and impact.

Read the Journal          Article Alerts          Submit Now